Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells
Zisheng Huang, Mahmoud Osman Khalifa, Peilin Li, Yu Huang, Weili Gu, Tao‐Sheng Li
2022American Journal of Physiology-Gastrointestinal and Liver Physiology20 citationsDOIOpen Access PDF
Abstract
Our ex vivo and in vivo experiments clearly indicated that low-dose losartan alleviated liver fibrosis, likely by modulating the mechanotransduction properties of HSCs. Uncovering the biomechanical signaling pathway of ARB treatment on liver fibrosis will be helpful to develop novel molecular targeting therapy for liver diseases.
Topics & Concepts
LosartanHepatic stellate cellAngiotensin IIFibrosisIn vivoMechanotransductionEx vivoDownregulation and upregulationHydrostatic pressureMedicinePharmacologyHepatic fibrosisChemistryInternal medicineEndocrinologyReceptorCancer researchCell biologyBiologyBiochemistryGeneThermodynamicsBiotechnologyPhysicsLiver physiology and pathologyLiver Disease Diagnosis and TreatmentEndoplasmic Reticulum Stress and Disease